Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
1.600
-0.020 (-1.23%)
At close: Nov 22, 2024, 4:00 PM
1.680
+0.080 (5.00%)
After-hours: Nov 22, 2024, 6:04 PM EST

Company Description

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific.

It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.

It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats.

In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs.

It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations.

It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022.

Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Standard BioTools Inc.
Standard BioTools logo
Country United States
Founded 1999
IPO Date Feb 10, 2011
Industry Medical Devices
Sector Healthcare
Employees 539
CEO Michael Egholm

Contact Details

Address:
2 Tower Place, Suite 2000
South San Francisco, California 94080
United States
Phone 650 266 6000
Website standardbio.com

Stock Details

Ticker Symbol LAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001162194
CUSIP Number 34385P108
ISIN Number US34385P1084
Employer ID 77-0513190
SIC Code 3826

Key Executives

Name Position
Dr. Michael Egholm Ph.D. President, Chief Executive Officer and Director
Hanjoon Kim Interim Chief Financial Officer and Chief Operating Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 144 Filing
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 8-K Current Report
Nov 6, 2024 10-Q Quarterly Report
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 30, 2024 8-K Current Report
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 21, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals